US-based biotechnology firm that develops novel anticancer therapeutics using antibody-drug conjugate (ADC) technology, ImmunoGen (IMGN) has signed a licensing agreement with Novartis, pursuant to which, Novartis has the exclusive right to ...
Tags: Immunogen, Novartis, ADC Technology
Genentech, a member of the Roche Group, has announced that the US Food and Drug Administration (FDA) has accepted and filed the company's supplemental biologics license application (sBLA) for subcutaneous use of Xolair (omalizumab) in ...
One of the world's top-selling drugs—GlaxoSmithKline PLC's $8-billion-a-year asthma treatment Advair—became more vulnerable to generic competition after the U.S. Food and Drug Administration issued guidance on the regulatory ...
Adimab signed a multi-target discovery agreement with Celgene Corporation, pursuant to which, Adimab will use its proprietary discovery and optimization platform to generate fully human antibodies against multiple targets. Under the terms ...
Tags: Adimab, Drug Discovery
The Australian Therapeutic Goods Administration (TGA) has granted approval for Novartis' multi-component Meningococcal B (MenB) vaccine, Bexsero, for use against a dangerous form of bacterial meningitis, MenB disease. The approval will ...
Tags: Menb Disease, Medicine
China is intensifying its investigation into alleged bribery in the pharmaceutical and medical services sector with a fresh three-month probe due to begin today. The investigation by the State Administration for Industry and Commerce, a ...
Tags: milk powder, medicine pricing
Ensemble Therapeutics has entered into two-part research and development collaboration with Novartis for oral, macrocyclic inflammatory cytokine IL-17 antagonists and additional disease targets. The collaboration will leverage Ensemble's ...
Tags: Ensemble Therapeutics, Novartis
The US Food and Drug Administration (FDA) has expanded age indication for Novartis' Menveo (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) to include infants and toddlers aged two months and ...
Swiss drugmaker Novartis has announced that once-daily dual bronchodilator, Ultibro Breezhaler (QVA149), has achieved positive CHMP opinion for the treatment of chronic obstructive pulmonary disease (COPD). Ultibro Breezhaler was ...
Novartis has received an approval from the European Commission for its Lucentis (ranibizumab) to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). Lucentis is a ...
Global pharma companies Sanofi, Novartis and GSK are competing to acquire the domestic formulations business of debt-burdening Elder Pharmaceuticals. People familiar with the matter were quoted by media sources as saying that Sanofi and ...
Tags: Domestic Formulations, Medicine
Biopharmaceutical company ThromboGenics' Jetrea has received approval from UK's National Institute for Health and Care Excellence (NICE) in the treatment of some adults with vitreomacular traction (VMT), a rare eye condition. Known as ...
Tags: Eye Condition Treatment, Medicine
Alliance Pharmaceuticals Limited, a wholly owned subsidiary of Alliance Pharma, has purchased all the existing rights to obstetric drug Syntometrine from Novartis for $11.5m. The total consideration for acquiring the rights will be funded ...
Tags: Obstetric Drug, Medicine
GlaxoSmithKline (GSK) has acquired a Switzerland-based vaccines company, Okairos, for €250m in cash to boost its existing vaccine platform technology expertise and to continue developing the next generation of vaccines. Under the ...
Tags: Glaxosmithkline, Vaccines Business
Integrated biopharmaceutical company ThromboGenics has announced the launch of Jetrea in Denmark and Sweden by Alcon, a division of Novartis. Alcon expects to roll out the European Commission approved Jetrea, which is indicated for the ...